Standout Papers

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial 2002 2026 2010 2018 3.1k
  1. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial (2002)
    Stephen B. Hanauer, Brian G. Feagan et al. The Lancet
  2. Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis (2013)
    Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine
  3. Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial (2006)
    Stephen B. Hanauer, William J. Sandborn et al. Gastroenterology
  4. Inflammatory bowel disease: Epidemiology, pathogenesis, and therapeutic opportunities (2005)
    Stephen B. Hanauer Inflammatory Bowel Diseases
  5. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab (2007)
    William J. Sandborn, Paul Rutgeerts et al. Annals of Internal Medicine
  6. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease (2004)
    Paul Rutgeerts, Brian G. Feagan et al. Gastroenterology
  7. Natalizumab Induction and Maintenance Therapy for Crohn's Disease (2005)
    William J. Sandborn, Jean‐Frédéric Colombel et al. New England Journal of Medicine
  8. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011)
    Walter Reinisch, William J. Sandborn et al. Gut
  9. Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed (2014)
    Bruce E. Sands, Brian G. Feagan et al. Gastroenterology
  10. Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis (2011)
    Alexander C. Ford, William J. Sandborn et al. The American Journal of Gastroenterology
  11. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) (2011)
    Simon Travis, Dan Schnell et al. Gut
  12. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis (2016)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  13. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis (2021)
    William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine
  14. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions (2015)
    Laurent Peyrin‐Biroulet, Julián Panés et al. Clinical Gastroenterology and Hepatology

Immediate Impact

1 by Nobel laureates 3 from Science/Nature 239 standout
Sub-graph 1 of 10

Citing Papers

Crohn's disease
2024 Standout
Ulcerative Colitis in Adults
2023 Standout
364 intermediate papers

Works of Stephen B. Hanauer being referenced

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis
2021 Standout
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
and 124 more

Author Peers

Author Last Decade Papers Cites
Stephen B. Hanauer 18615 14207 6145 398 24.1k
Simon Travis 14524 11373 7291 419 21.1k
Walter Reinisch 13684 10707 5093 334 19.2k
Anne M. Griffiths 15754 11072 7093 361 22.4k
Stephan R. Targan 17995 12274 5869 428 30.4k
Daniel Rachmilewitz 13437 10262 6122 196 21.1k
Julián Panés 13720 10880 8255 570 25.1k
Gert Van Assche 26295 20158 10425 445 35.8k
Stephen B. Hanauer 25150 18694 8824 154 33.0k
Remo Panaccione 25603 18908 9789 684 35.4k
Antoine Cortot 11509 8183 5930 274 19.0k

All Works

Loading papers...

Rankless by CCL
2026